WO2007120868A3 - Bioavailability enhancement of lipophilic drug by use solvent system - Google Patents

Bioavailability enhancement of lipophilic drug by use solvent system Download PDF

Info

Publication number
WO2007120868A3
WO2007120868A3 PCT/US2007/009229 US2007009229W WO2007120868A3 WO 2007120868 A3 WO2007120868 A3 WO 2007120868A3 US 2007009229 W US2007009229 W US 2007009229W WO 2007120868 A3 WO2007120868 A3 WO 2007120868A3
Authority
WO
WIPO (PCT)
Prior art keywords
disclosed
compositions
solvent system
use solvent
methods
Prior art date
Application number
PCT/US2007/009229
Other languages
French (fr)
Other versions
WO2007120868A2 (en
Inventor
Stanley Kepka
Original Assignee
Stanley Kepka
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stanley Kepka filed Critical Stanley Kepka
Publication of WO2007120868A2 publication Critical patent/WO2007120868A2/en
Publication of WO2007120868A3 publication Critical patent/WO2007120868A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers

Landscapes

  • Health & Medical Sciences (AREA)
  • Dermatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Compositions and methods for improving the efficacy and/or transdermal transport of topically administered pharmacologically active compounds are disclosed. Preferably, the pharmacologically active compound is incorporated in a carrier comprising an effective amount of a lipophilic pharmaceutically acceptable compound selected from the group consisting of alcohol, glycols, ethers and mixtures thereof, most preferably benzyl alcohol. In certain embodiments, compositions and methods of treatment for anti-fungal compositions are disclosed that exhibit enhanced permeation. In another embodiment and improved, stable topical composition of prostaglandin is disclosed.
PCT/US2007/009229 2006-04-14 2007-04-16 Bioavailability enhancement of lipophilic drug by use solvent system WO2007120868A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79218606P 2006-04-14 2006-04-14
US60/792,186 2006-04-14

Publications (2)

Publication Number Publication Date
WO2007120868A2 WO2007120868A2 (en) 2007-10-25
WO2007120868A3 true WO2007120868A3 (en) 2007-12-06

Family

ID=38610230

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/009229 WO2007120868A2 (en) 2006-04-14 2007-04-16 Bioavailability enhancement of lipophilic drug by use solvent system

Country Status (1)

Country Link
WO (1) WO2007120868A2 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8987238B2 (en) 2012-06-18 2015-03-24 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US8987237B2 (en) 2011-11-23 2015-03-24 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US9289382B2 (en) 2012-06-18 2016-03-22 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
AU2015264003A1 (en) 2014-05-22 2016-11-17 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
AU2015296609A1 (en) 2014-07-29 2016-12-22 Therapeuticsmd, Inc. Transdermal cream
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
WO2017173071A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
CA3164165A1 (en) 2020-01-10 2021-07-15 Robert Bruce Register Topical compositions containing rofecoxib and methods of making and using the same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MURDAN: "Drug delivery to the nail following topical application", INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. 236, no. 1-2, 2 April 2002 (2002-04-02), pages 1 - 26, XP008091512 *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8987237B2 (en) 2011-11-23 2015-03-24 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US8993548B2 (en) 2011-11-23 2015-03-31 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US8993549B2 (en) 2011-11-23 2015-03-31 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9114146B2 (en) 2011-11-23 2015-08-25 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9114145B2 (en) 2011-11-23 2015-08-25 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9248136B2 (en) 2011-11-23 2016-02-02 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US8987238B2 (en) 2012-06-18 2015-03-24 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9006222B2 (en) 2012-06-18 2015-04-14 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9012434B2 (en) 2012-06-18 2015-04-21 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9289382B2 (en) 2012-06-18 2016-03-22 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion

Also Published As

Publication number Publication date
WO2007120868A2 (en) 2007-10-25

Similar Documents

Publication Publication Date Title
WO2007120868A3 (en) Bioavailability enhancement of lipophilic drug by use solvent system
WO2010136474A3 (en) Substituted aminobutyric derivatives as neprilysin inhibitors
WO2008008397A3 (en) Fatty acid pharmaceutical foam
WO2007022255A3 (en) Pharmaceutical formulations for sustained release
WO2007145991A3 (en) Anti-inflammatory and analgesic compositions and related methods
WO2008057802A3 (en) Compositions comprising at least one acid labile proton pump inhibiting agents, optionally other pharmaceutically active agents and methods of using same
WO2010150995A3 (en) Compositions for treating drug addiction and improving addiction-related behavior
NO20073959L (en) Quinazoline derivative, method of preparation and use thereof for inhibiting cancer cell growth
WO2011014850A3 (en) Topical eutectic-based formulations
BR0313575A (en) Method of transdermal transport of topically administered pharmaceutical products, vehicle, vehicle composition, pharmaceutical composition and use of one or more phosphate derivative complexes of lipophilic pharmaceutically acceptable compounds with other excipients
WO2006083780A3 (en) Glucuronidated nebivolol
JP2010535814A5 (en)
WO2008144269A3 (en) Methods for using vasopressin antagonists with anthracycline chemotherapy agents to reduce cardiotoxicity and/or improve survival
AR048336A1 (en) HYDROCLORIDE OF (4- (5-AMINOMETIL-2-FLUORO-PHENYL) -PIPERIDIN-1-IL) - (4-BROMO-3-METHYL-5-PROPOXI-TIOFEN-2-IL) -METANONE AS AN INHIBITOR OF THE MASTOCYT TRIPTASE
WO2006050002A3 (en) Compositions for controlled delivery of pharmaceutically active compounds
WO2005117895A8 (en) Compositions comprising meloxicam
WO2011017195A3 (en) Topical pharmaceutical preparations having both a nanoparticle solution and a nanoparticle suspension and methods for the treatment of acute and chronic pain therewith
WO2007133751A3 (en) Base-stabilized polyorthoester formulations
WO2008023016A3 (en) Galenic formulations of aliskiren
WO2005123192A3 (en) Improving pain treatment with strontium combinations
EP1798234A4 (en) Pharmaceutical composition comprising temozolomide ester
WO2011076209A3 (en) Pharmaceutical composition comprising solvent mixture and a vitamin d derivative or analogue
EP2316420A8 (en) Method to reduce pain
BRPI0506496A (en) antimicrobial preservatives for obtaining multidose formulation using beta-cyclodextrins for liquid dosage forms
AR064152A1 (en) ANTIBACTERIAL QUINOLINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND PREPARATION METHOD.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07755482

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07755482

Country of ref document: EP

Kind code of ref document: A2